Alexandre Williams, founder and managing director of Athena, an international company with an Indian manufacturing basis specialized in life cycle products, provides insights into some key trends shaping India’s pharmaceutical industry and exports. He also documents Athena’s plan to launch over 50 new products in both advanced and strategic emerging markets in the coming years and highlights how the company has been targeting both specialty pharma companies and pure generics players interested in differentiated, branded generics.
India based manufacturers have been very successful on the international stage over the past fifteen years, by notably leveraging the country’s competitive manufacturing cost advantage. Leveraging on your experience, what have been some other key success factors that our readers might not know?
"We have a solid strategy for emerging markets, and – despite our smaller size – we actually follow the same approach as some multinational companies."
